Osilodrostat
Chemical compound / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Osilodrostat?
Summarize this article for a 10 year old
Osilodrostat, sold under the brand name Isturisa, is a medication for the treatment of adults with Cushing's disease who either cannot undergo pituitary gland surgery or have undergone the surgery but still have the disease.[3] It is taken by mouth.[3]
Clinical data | |
---|---|
Trade names | Isturisa |
Other names | LCI-699 |
AHFS/Drugs.com | Monograph |
License data | |
Pregnancy category | |
Routes of administration | By mouth |
Drug class | Steroidogenesis inhibitor |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C13H10FN3 |
Molar mass | 227.242 g·mol−1 |
3D model (JSmol) | |
| |
|
The most common side effects are adrenal insufficiency, headache, vomiting, nausea, fatigue, and edema (swelling caused by fluid retention).[3][4]
Hypocortisolism (low cortisol levels), QTc prolongation (a heart rhythm condition) and elevations in adrenal hormone precursors (inactive substance converted into a hormone) and androgens (hormone that regulates male characteristics) may also occur in people taking osilodrostat.[3]
Osilodrostat was approved for medical use in the European Union in January 2020,[4] and for medical use in the United States in March 2020.[3][5][6] The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.[7]
Osilodrostat is an orally active, nonsteroidal corticosteroid biosynthesis inhibitor which was developed by Novartis for the treatment of Cushing's syndrome and pituitary ACTH hypersecretion (a specific subtype of Cushing's syndrome).[8] It specifically acts as a potent and selective inhibitor of aldosterone synthase (CYP11B2) and at higher dosages of 11β-hydroxylase (CYP11B1).[8]